

September 30, 2025

Genomtec Newsletter

Dear All,

We encourage you to read our latest newsletter, which contains a summary of key events from recent weeks.



Financial results

On September 29, 2025, the periodic report of Genomtec SA for the period from January to the end of June (first half of 2025) was published.

The full report is available on the Genomtec website in the investor section: <https://genomtec.com/raporty/#okresowe>



New patents

On September 25, 2025, Genomtec received patent protection from the European Patent Office for the invention entitled: "Set of primers, composition of reagents and method for detecting atypical bacteria".

The development of a primer set is a key element of Genomtec's LAMP-based diagnostic method. Primers initiate the amplification reaction by recognizing a characteristic fragment of the pathogen's genome. Importantly, the number of primer sets that can be designed for a given pathogen using the LAMP technique is typically extremely limited. Such patent applications protect against the risk of competitors using the same primer set and limit their ability to develop equally rapid, sensitive, and specific diagnostic tests.

On September 15, 2025, the Company received notification that the Japanese Patent Office had granted it a patent for an invention for detecting HPV16 and HPV18 viruses. Protection is valid until 2040. This is the third patent granted to the Company in Japan.

In total, Genomtec has already been granted 16 patents worldwide, and over 30 more applications are pending.

Publications and media

- Dr. hab. Małgorzata Małodobra-Mazur, Director of Research and Development and co-founder of Genomtec, in an interview with the Włączeni Plus Foundation, talks about how we combine science with practice, proving that innovations are not born in isolation from reality, but in response to specific medical needs.

The entire interview can be read on Onet.pl: <https://www.onet.pl/styl-zycia/wlaczeniplus/dr-malgorzata-malodobra-mazur-o-innowacjach-w-medycynie/2jtjgv4,0666d3f1>

- Dr. Miron Tokarski, CEO of Genomtec, discusses with Marcin Podlacki how our innovations can transform the global diagnostics market. The interview is available on YouTube: <https://www.youtube.com/watch?v=bHFzBxiXQ3k>
- During the ADLM conference in Chicago (July 2025), Miron Tokarski, in a short interview, emphasized the growing need for infectious disease testing and the importance of advanced genetic diagnostic tests. Link to the recording: <https://www.youtube.com/watch?v=K-dmSzHWm7w>

Contact: Genomtec Investor Relations Team  investors@genomtec.com